过氧化物酶体增长因子活化受体γ与维甲酸类X受体在胆管癌中的表达及其对预后的影响  

Expression of PPARγ and RXRa in cholangiocarcinoma and its impact on prognosis

作　　者：刘兵[1] 王文斌[2] 刘明[1] 王安峰[1] 徐袁秋[1] 

机构地区：[1]河北医科大学第三医院放疗科,石家庄050051 [2]河北医科大学第二医院肝胆外科,石家庄050000

出　　处：《中华肝胆外科杂志》2010年第11期835-838,共4页Chinese Journal of Hepatobiliary Surgery

基　　金：河北省卫生厅医学科学研究重点课题计划指令性项目编号：08141

摘　　要：目的 探讨胆管癌组织中过氧化物酶体增长因子活化受体γ（PPARγ）和维甲酸类X受体（RXRα）蛋白的表达与胆管癌临床病理特征的关系及其对预后的影响.方法 采用免疫组化法检测69例胆管癌以及12例非肿瘤胆管黏膜上皮组织中PPARγ与RXRα的表达情况,并分析其与临床病理参数及预后的关系.结果 69例胆管癌组织、12例非肿瘤胆管黏膜上皮组织中PPARγ表达阳性率分别为59.4%、0;69例胆管癌组织、12非肿瘤胆管黏膜上皮组织中RxRα表达阳性率分别为78.3%、20%,差异有统计学意义.PPARγ蛋白的阳性表达与胆管癌TNM分期、淋巴结转移密切相关,PPARγ蛋白阳性表达组胆管癌病人的预后差.PPARγ与RXRα存在明显的正相关关系.结论 PPARγ表达与胆管癌临床病理特征密切相关.PPARγ和RXRα两者可能参与了胆管上皮癌变过程.Objective To evaluate the expression of peroxisome proliferator-activated receptor γ（PPARγ）and retinoid x receptorα（RXRα）in cholangiocarcinoma to explore its relation to clinicopathological factors and investigate its impact on prognosis.Methods Expression of PPARγ and RXRα was detected by immunohistochemistry in 69 cases of cholangiocarcinoma and 12 non-tumor cases.The relation of PPARγ and RXRα expression to clinicopathological parameters and prognosis was determined.Results The expression rates of PPARγ in 69 cases of cholangiocarcinoma and 12 non-tumor cases were 59.4% and 0, respectively（P〈0.05）.The expression rates of RXRα in 69 cases of cholangiocarcinoma and 12 non-tumor cases were 78.3% and 20%, respectively.There were significant differences between the 2 groups in PPARγ and RXRα expression.PPARγ expression was associated with TNM clinical stages and lymph node metastasis.According to univariate survival analysis,PPARγ expression was correlated with poor prognosis（P〈0.05）.There was positive correlation between PPARγ and RXRα.Conclusion The expression of PPARγis significantly correlated with the clinicopathological characteristics and biological behaviors of cholangiocarcinoma.PPARγ and RXRα expression may play an important role during tumorigenesis.

关 键 词：胆管肿瘤 过氧化物酶体增长因子活化受体γ 维甲酸类x受体α 预后 转移 

分 类 号：R686[医药卫生—骨科学]